Document is current
Any future updates will be listed below
-
Authors
Resch, Erin E.
Makri, Stavriani C.
Ghanem, Paola
Baraban, Ezra G.
Cohen, Kenneth J.
Cohen, Alan R.
Lipson, Evan J.
Pratilas, Christine A. https://orcid.org/0000-0002-7116-0605
-
Funding
Funding for this research was provided by:
Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
The Marilyn and Michael Glosserman Fund for Basal Cell Carcinoma and Melanoma Research
The Barney Family Foundation
- License Information
-
More Information
Article History
Received: 23 September 2024
Accepted: 28 January 2025
First Online: 21 February 2025
Competing interests
: C.A.P. has received research grants from Kura Oncology and Novartis Institutes for Biomedical Research (unrelated to this manuscript) and consulting fees from Day One Therapeutics (unrelated). Related to this manuscript, E.J.L. has received support from the Bloomberg~Kimmel Institute for Cancer Immunotherapy, the Marilyn and Michael Glosserman Fund for Basal Cell Carcinoma and Melanoma Research, the Barney Family Foundation, and the Laverna Hahn Charitable Trust. E.J.L is a consultant/advisor for Agenus, Bristol-Myers Squibb, CareDx, Eisai, Genentech, HUYA Bioscience International, Immunocore, Instil Bio, Lyvgen, Merck, Merck KGaA, Natera, Nektar, Novartis, OncoSec, Pfizer, Rain Therapeutics, Regeneron, Replimune, Sanofi-Aventis, Sun Pharma, Syneos Health (unrelated). E.J.L. has institutional research funding from Bristol-Myers Squibb, Haystack Oncology, Merck, Regeneron, Sanofi (unrelated). EJ.L holds stock in Iovance Biotherapeutics (unrelated). The other co-authors declare that they have no competing interests.
